A detailed history of Eco R1 Capital, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Eco R1 Capital, LLC holds 3,249,835 shares of ITOS stock, worth $28.6 Million. This represents 1.7% of its overall portfolio holdings.

Number of Shares
3,249,835
Previous 1,999,249 62.55%
Holding current value
$28.6 Million
Previous $27.3 Million 76.86%
% of portfolio
1.7%
Previous 0.78%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $12.9 Million - $22.6 Million
1,250,586 Added 62.55%
3,249,835 $48.2 Million
Q1 2024

May 15, 2024

BUY
$9.89 - $13.64 $8.75 Million - $12.1 Million
884,227 Added 79.3%
1,999,249 $27.3 Million
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $9.56 Million - $12.3 Million
1,115,022 New
1,115,022 $12.2 Million
Q1 2023

May 15, 2023

SELL
$13.02 - $22.62 $510,123 - $886,251
-39,180 Reduced 96.79%
1,300 $17,000
Q3 2022

Nov 14, 2022

SELL
$18.6 - $27.25 $4.46 Million - $6.53 Million
-239,519 Reduced 85.54%
40,480 $771,000
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $3.43 Million - $7.27 Million
207,178 Added 284.5%
279,999 $5.77 Million
Q1 2022

May 16, 2022

SELL
$31.92 - $47.45 $39.3 Million - $58.4 Million
-1,230,336 Reduced 94.41%
72,821 $2.34 Million
Q3 2021

Nov 15, 2021

BUY
$23.91 - $29.58 $6.39 Million - $7.91 Million
267,293 Added 25.8%
1,303,157 $35.2 Million
Q2 2021

Aug 16, 2021

BUY
$17.9 - $36.1 $13.9 Million - $28 Million
775,864 Added 298.41%
1,035,864 $26.6 Million
Q3 2020

Nov 16, 2020

BUY
$17.57 - $32.92 $4.57 Million - $8.56 Million
260,000 New
260,000 $6.41 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $313M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.